profiling of obese individuals revealed altered concentrations of many metabolites, especially branched-chain amino acids (BCAA), possibly linked to altered adipose tissue BCAA catabolism. We tested the hypothesis that some features of this metabolite signature relate closely to visceral obesity and concomitant alterations in cardiometabolic risk factors. We also postulated that alterations in BCAA-catabolizing enzymes are predominant in visceral adipose tissue. Fifty-nine women (BMI 20 -41 kg/m 2 ) undergoing gynecologic surgery were recruited and characterized for overall and regional adiposity, blood metabolite levels using targeted metabolomics, and cardiometabolic risk factors. Adipose samples (visceral and subcutaneous) were obtained and used for gene expression and Western blot analyses. Obese women had significantly higher circulating BCAA and kynurenine/tryptophan (Kyn/Trp) ratio than lean or overweight women (P Ͻ 0.01). Principal component analysis confirmed that factors related to AA and the Kyn/Trp ratio were positively associated with BMI, fat mass, visceral or subcutaneous adipose tissue area, and subcutaneous adipocyte size (P Յ 0.05). AA-related factor was positively associated with HOMA-IR (P Յ 0.01). Factors reflecting glycerophospholipids and sphingolipids levels were mostly associated with altered blood lipid concentrations (P Յ 0.05). Glutamate level was the strongest independent predictor of visceral adipose tissue area (r ϭ 0.46, P Ͻ 0.001). Obese women had lower expression and protein levels of BCAA-catabolizing enzymes in visceral adipose tissue than overweight or lean women (P Յ 0.05). We conclude that among metabolites altered in obesity plasma concentrations of BCAA and the Kyn/Trp ratio are closely related to increased adiposity. Alterations in expression and protein levels of BCAA-catabolizing enzymes are predominant in visceral adipose tissue.
Metabolomics may offer a broader insight into our understanding of the metabolic alterations related to central distribution of fat in obesity (58) .
Several metabolites have been examined as potential biomarkers of obesity and cardiometabolic alterations. Phosphatidylcholine (PC) is the main circulating phospholipid and is mostly found on HDL particles; it plays a role in the regulation of circulating lipoprotein levels, especially VLDL (7) . Plasma PC levels were found to be altered in the obese state and may be involved in obesity-related hepatic steatosis (49) . Sun et al. (43) observed high blood PC levels as well as elevated cholesterol and triglyceride concentrations in pigs fed a high-fat diet without weight gain compared with animals fed a control diet. Lysophosphatidylcholines (lysoPC) are hydrolyzed derivatives of PC, and studies have demonstrated that these compounds play a role in the development of atherosclerosis and hyperlipidemia (27, 30) . They are components of oxidized LDL cholesterol particles, which are related to the risk of cardiovascular disease (16, 26) . Sphingolipids, particularly sphingomyelins (SM), are ceramide precursors and usually colocalize with cholesterol on cell membranes and LDL surface (21) . Evidence suggests that ceramide concentrations are associated with insulin resistance (12, 21, 46) . The ratio of kynurenine to tryptophan levels (Kyn/Trp), an increasingly recognized marker of inflammation and metabolic alterations, has been shown to be high in adult overweight or obese individuals (24, 53) , and also appears to be related to waist circumference independent of age (24) .
Many studies also focused on amino acids (AA) in the context of obesity (38, 44, 50, 54) . Most reported elevated plasma levels of branched-chain amino acids (BCAA; leucine, isoleucine, valine) in obese children, adolescents, and adults compared with their lean counterparts (1, 5, 18, 29, 32, 33, 50, 58) , and weight loss was associated with lower BCAA levels (39) . Circulating alanine, phenylalanine, tyrosine, glutamate/ glutamine, aspartate/asparagine, and arginine have also been shown to be increased in obese individuals (33) . Significantly higher plasma BCAA, aromatic amino acids (AAA), and C3 and C5 acylcarnitine levels are also found among metabolically unwell versus metabolically well individuals, independent of BMI (3) . Results regarding alterations in other AA remain inconsistent (3, 18, 33) .
BCAA catabolism occurring in peripheral tissues involves their initial, reversible transformation into ␣-ketoacids by branched-chain amino acid aminotransferase (BCATm), fol-lowed by irreversible decarboxylation of these compounds to acyl-CoA esters by the branched-chain ketoacid dehydrogenase complex (BCKDC) (15) . Branched-chain ketoacid dehydrogenase kinase (BCKDK) acts as an inhibitor of BCKDC through phosphorylation (15) , which can be reversed by branched-chain ketoacid dehydrogenase phosphatase (PP2Cm) (59) . Obesity-related increases in circulating BCAA and other AA could be due to a defect in BCAA-catabolizing enzymes in adipose tissue (15, 19) .
While many studies have focused on plasma metabolite alterations in obesity, insulin resistance, and type 2 diabetes, only a few studies have considered body fat distribution, other markers of cardiometabolic risk (13, 44, 55) , and possible depot-specific alterations in BCAA-catabolizing enzymes (15, 19) . In addition, only one study has performed metabolomicsbased AA analysis including human visceral and subcutaneous adipose tissue from nonobese and obese individuals (13) . Thus, we attempted to identify which features of the plasma metabolite signature of obesity were related to visceral obesity and cardiometabolic risk factors and assessed possible depot-specific alterations in expression and protein levels of BCAAcatabolizing enzymes in visceral and subcutaneous adipose tissue. We tested the hypothesis that some features of the metabolite profile relate closely to visceral obesity and concomitant alterations in cardiometabolic risk factors. We also postulated that alterations in BCAA-catabolizing enzymes are especially apparent in visceral adipose tissue.
SUBJECTS AND METHODS

Subjects.
Women were recruited at the Gynecology Unit of the Centre Hospitalier Universitaire (CHU) de Quebec. The project was approved by the Medical Ethics Committee of the Institution. Written, informed consent was obtained from all prospective participants before they were included in the study. None of the women quit the study. We selected patients for whom blood samples had never been thawed and for whom visceral and subcutaneous adipose tissue samples as well as axial computed tomography data were available. A sample of 59 healthy women aged 37.7 to 59.4 yr was studied. Menopausal status could be determined for 56 women and was based on FSH level, reported presence/absence of menstrual bleeding, and regularity of the menstrual cycle. A total of 39 women were considered pre-or perimenopausal, and 17 were considered postmenopausal. Women elected for total (n ϭ 56) or subtotal (n ϭ 1) abdominal hysterectomies, some with salpingooophorectomy of one (n ϭ 12) or two (n ϭ 16) ovaries. Three women underwent surgery for myomectomy by laparotomy or cauterization of endometrial lesions. Characteristics of the women included in this study are shown in Table 1 .
Body fatness and body fat distribution measurements. These data were collected a few days prior to or on the morning of surgery. Dual-energy X-ray absorptiometry was performed with a Hologic QDR-4500A densitometer, and the WholeBody Fan Beam software v.8.269:3 (Hologic, Bedford, MA) was used to measure total body fat mass, fat percentage, and lean body mass. Visceral and subcutaneous adipose tissue cross-sectional areas were measured by computed tomography with a GE Light Speed 1.1 CT scanner (General Electric Medical Systems, Milwaukee, WI). To perform the test, women had to lie in the supine position, their arms stretched above the head. To determine scanning position, a scout image of the body was used, and images were obtained at the level of the L4 -L5 vertebrae. To obtain visceral adipose tissue area, the intra-abdominal cavity was delineated using the ImageJ 1.33u software (National Institutes of Health, Bethesda, MD) at the internalmost aspect of the abdominal and oblique muscle walls around the cavity as well as the posterior aspect of the vertebral body. The area of subcutaneous adipose tissue was then calculated by subtraction of measured visceral adipose tissue area from total adipose tissue area at L4-L5. Highlighting and computation of adipose tissue areas were performed within the attenuation range of Ϫ190 to Ϫ30 Hounsfield units. All images were analyzed by the same observer.
Plasma Glucose homeostasis, adipokines, and inflammatory markers. The glucose oxidase method was used to assess plasma glucose. Plasma insulin levels were measured by ELISA (Millipore, Billerica, MA, or ALPCO, Salem, NH). These data were then used to calculate the homeostasis model assessment (HOMA) insulin resistance (IR) index (28) . Plasma IL-6 and TNF-␣ concentrations were measured with assay kits from R&D Systems (Minneapolis, MN); plasma adiponectin levels were assessed with an assay kit from B-Bridge International (Cupertino, CA), and leptin levels were measured with an assay kit from EMD Millipore (Billerica, MA).
Adipose tissue sampling and adipocyte isolation. Subcutaneous adipose tissue samples were collected at the site of surgical incision (lower abdomen), and visceral adipose tissue samples were taken from the distal portion of the greater omentum. They were immediately carried to the laboratory, and a portion of fresh tissue was kept for adipocyte isolation and cell sizing as previously described (31) .
Metabolomics analysis. Targeted metabolomics analysis in plasma samples was performed at the Helmholtz Zentrum München, Institute of Experimental Genetics, Genome Analysis Center, in Neuherberg, Germany. Metabolites were quantified in 10 l of plasma using the AbsoluteIDQ kit p180 (BIOCRATES, Innsbruck, Austria) and ESI-LC-MS/MS and ESI-MS/MS measurements. Assay procedures of the kit and metabolite nomenclature have been described previously (36, 37) . Sample handling was performed by a Hamilton Microlab STAR robot (Hamilton Bonaduz, Bonaduz, Switzerland) and an Ultravap nitrogen evaporator (Porvair Sciences, Leatherhead, UK). MS analyses were carried out on an API 4000 LC-MS/MS System (AB Sciex Deutschland, Darmstadt, Germany) equipped with a 1200 Series HPLC (Agilent Technologies Deutschland, Boeblingen, Germany) and HTC PAL autosampler (CTC Analytics, Zwingen, Switzerland) controlled by the Analyst 1.5.1 software. Data evaluation for quantification of metabolite concentrations and quality assess-ment were performed with the MetIDQ software package. Internal standards were used to calculate concentrations of 188 metabolites, including free carnitine, acylcarnitines, AAs, biogenic amines, lysoPCs, PCs, and SMs. Concentrations were expressed as micromoles per liter.
Gene expression analysis. A subgroup of patients (n ϭ 20) covering a wide range of adiposity and visceral adipose tissue area was selected. Total RNA was extracted using the RNeasy lipid tissue extraction kit and on-column DNase treatment (Qiagen, Valencia, CA) from whole adipose tissues. Quantification of total RNA was performed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE), and total RNA quality was assayed using the Agilent BioAnalyzer (Agilent Technologies, Santa Clara, CA). Firststrand cDNA synthesis was accomplished using Superscript III Rnase H-RT (Invitrogen Life Technologies, Burlington, ON, Canada) and purified with PCR purification kit (Qiagen, Hilden, DE). Oligoprimer pairs were designed by GeneTool 2.0 software (Biotools, Edmonton, AB, Canada), and their specificity was verified by BLAST in the GenBank database. The synthesis was performed by IDT (Integrated DNA Technology, Coralville, IA). Primer sequences were as follows: BCKDHA, GATGACAAGCCCCAGTTCCCA/TGGGGTT-GATGATCTGGCCTT; BCKDHB, GCGGCAGGTGGCT-CATTTTACT/CAGTAGGATCTTTGGCCAATGAGTTAT; BCAT1, GGTCCCATATTCAACATCTGCTAGTCT/TC-CCATCTTGCAGTCCCCAGT; BCAT2, TTACGCGCCG-CACGGATCAT/GGTCGGTAAATGTCTTCCCAAAC; and BCKDK, CTCGGTACCTGCAGCAAGAACTT/ATCG-GAGGGAAGTCTGTCAGCT.
Complementary DNA was used to perform fluorescentbased real-time PCR quantification using the LightCycler 480 (Roche Diagnostics, Mannheim, DE). Calculation of the number of copies of each mRNA was performed according to Luu-The et al. (22) . PCR amplification efficiency was verified. We assessed ATP synthase O subunit, hypoxanthine phosphoribosyltransferase-1 (HPRT1), glucose-6-phosphate dehydrogenase, and 18S ribosomal RNA (52) . Normalization was performed using HPRT1, as it showed the lowest variation among samples. Quantitative real-time RT-PCR measurements were performed by the CHU de Quebec Gene Expression Platform. Dietary data. Women completed a 3-day food record prior to the surgery (n ϭ 46). Dietary data were not available for 13 women. A research assistant reviewed the records with the help of a registered dietician and were able to call participants back to obtain more details. Dietary intakes were analyzed using the Nutrition Data System for Research (NDS-R) software v.4.02 (Minneapolis, MN).
Statistical analyses. Differences among BMI categories for plasma metabolite levels, gene expression, and protein level were assessed by one-way ANOVA. Principal component analysis (PCA) was used to reduce dimensionality of the dataset. Fourteen major principal components were examined after Varimax rotation. Factors were considered relevant if they had an eigenvalue above 1. Metabolites were included in a factor if their component load was Ն|0.5|. Metabolites included in each factor are presented in Table 2 Table 3 . Factor 1 included all AAs except aspartate and glutamate, biogenic amines derived from AA metabolism, C4 acylcarnitines, C5 acylcarnitines, and free carnitines. This factor explained 50% of the variance in our data set (P Ͻ 0.0001).
Adiposity markers. Factor 1 was positively correlated with several adiposity markers including BMI, total body fat mass, visceral adipose tissue area, subcutaneous adipose tissue area, and subcutaneous cell size. A factor related to the Kyn/Trp ratio also correlated with all adiposity markers. Factor 8, (Fig. 1) . Conversely, no difference was found for total lysoPC, PCae, and PCaa as well as total SM and SM(OH) among BMI categories.
We tested associations between levels of individual AAs and adiposity measurements (Table 4) . Concentrations of alanine, BCAA, tyrosine, and lysine were all positively correlated with several adiposity indexes (BMI, total body fat mass, subcutaneous and/or visceral adipose tissue areas). Concentrations of alanine, BCAA, glutamate, and tyrosine were positively associated with visceral adipose tissue area. The same variables were also related to subcutaneous adipose tissue area. Levels of isoleucine, leucine, and tyrosine were positively and significantly correlated to mean adipocyte diameter in both fat compartments. Glutamate level was the strongest independent predictor of visceral adipose tissue area (adjustment for total body fat mass) and was also positively associated with mean adipocyte size in visceral tissue only. Plasma alanine and arginine concentrations were related to larger subcutaneous adipocytes.
Lipid profile. The AA-related factor (Factor 1) was negatively associated with levels of HDL-cholesterol, HDL-triglycerides, and HDL-apoA-1. Positive associations were also observed between Factor 2 (reflecting almost all SM and 19 of the 35 PCae), and total, LDL-, and HDL-cholesterol as well as LDL-apoB levels. Negative correlations were observed between Factor 2 and VLDL-cholesterol, total and VLDL-triglycerides. Positive associations were found between Factor 3 (mainly PCaa and 2 lysoPC) and total, VLDL-, and HDLcholesterol concentrations. Factor 3 was also positively associated with total, VLDL-, and HDL-triglyceride as well as HDL-apoA-1 levels. The glutamate-C18-related factor correlated negatively with the total/HDL-cholesterol ratio and positively with total and VLDL-triglyceride levels. Factor 14 (Kyn/Trp ratio) was negatively associated with concentrations of HDL-cholesterol and HDL-apoA-1 and positively with the total/HDL-cholesterol ratio and LDL-triglycerides.
Glucose homeostasis, adipokines, and inflammatory markers. The AA-related Factor 1 was positively associated with fasting insulin and HOMA-IR. The glutamate-C18-related factor was also positively correlated with these variables. Factor 1 was positively associated with leptin and IL-6 concentrations. The factor related to the Kyn/Trp ratio was also positively associated with leptin levels. Negative correlations were also observed with adiponectin levels. Factor 11 was negatively Table shows factors for which significant correlation was observed with at least one variable. ***P Յ 0.0001, **P Յ 0.001, *P Յ 0.01, #P Յ 0.05; -, nonsignificant P value; a n ϭ 58, b n ϭ 57, c n ϭ 49. associated with TNF-␣ level. As shown in Table 4 , we also tested the association between plasma AA and HOMA-IR. There was a significant positive correlation between plasma leucine and HOMA-IR. Figure 2 shows the associations between each plasma AA and BMI before and after adjustment for HOMA-IR. Plasma lysine, arginine, threonine, tyrosine, phenylalanine, valine, leucine, isoleucine, and alanine were all positively associated with BMI both before and after adjustment. Plasma histidine, methionine, and proline were positively correlated to BMI only after adjustment for HOMA-IR. 
***P Յ 0.0001, **P Յ 0.001, *P Յ 0.01, #P Յ 0.05; -, nonsignificant P value; § remained significant after adjustment for total body fat mass; a n ϭ 58, b n ϭ 57.
The association between glutamate and BMI was no longer significant after adjustment.
Gene expression and protein levels. Considering the strong associations between levels of BCAA and adiposity measurements, we further investigated BCAA-catabolizing enzymes in visceral and subcutaneous adipose tissues. As shown in Fig.  3A , gene expression of BCKDHA and -B as well as BCAT2 were significantly decreased in visceral adipose tissue among women with a BMI Ͼ30 kg/m 2 compared with lean and overweight individuals (P Ͻ 0.05 for all). BCKDE1␣ mass and its phosphorylation on Ser 293 were also decreased in visceral adipose tissue of women with a BMI Ͼ30 kg/m 2 (Fig. 3B) . The ratio of p-BCKDE1␣ Ser 293 to BCKDE1␣ mass was not different among subgroups. Protein level of BCKDK slightly decreased in omental adipose tissue of obese women but did not reach statistical significance (Fig. 3B) . In the subcutaneous depot, only BCAT2 mRNA expression was decreased in obese women, and none of the proteins examined showed consistent obesity-related differences (Fig. 3, C and D) .
Dietary data. We assessed the association between blood and dietary AA, mean daily energy, and macronutrient intake. Mean energy intake was 2,088 calories per day. Mean values for percent energy from macronutrients were 46, 33, and 16% from carbohydrates, fat, and protein, respectively. There was no association between protein or dietary AA intake and blood AA concentrations (data not shown).
DISCUSSION
The aim of this study was to identify plasma metabolite patterns related to visceral obesity and concomitant alterations in cardiometabolic risk factors. We also aimed to identify adipose depot-specific alterations in BCAA-catabolizing enzymes in obesity. We found that blood levels of BCAA and the Kyn/Trp ratio were elevated in obese women. PCA showed that most AAs as well as some AA metabolites and short-chain acylcarnitines were positively associated with body fat mass, visceral and subcutaneous adipose tissue areas, subcutaneous adipocyte size, and markers of insulin resistance. Levels of PCae and SM were positively associated with cholesterol-rich lipoprotein levels, while PCaa were mostly related to lipid content of VLDL and HDL particles. Glutamate and C18 acylcarnitine concentrations were associated with visceral adipose tissue area, blood triglycerides, and glucose homeostasis markers; the former was the best independent predictor of visceral adipose tissue area. PCR analysis and Western blotting showed reduced expression and protein levels of enzymes involved in the second step of BCAA catabolism, specifically in visceral adipose tissue. To our knowledge, this study is the first to focus on the metabolomics signature of visceral obesity with comprehensive characterization of body composition, fat distribution, adipocyte hypertrophy, and cardiometabolic risk factors as well as gene expression and protein level of BCAAcatabolizing enzymes in the visceral and subcutaneous depot.
PCA showed that altered plasma levels of AA and some of their metabolites, such as kynurenine (Kyn) and C5 acylcarnitine, are associated with many adiposity markers, as reported by other groups (3, 24, 33, 42, 44) . One other study had examined associations between levels of glutamine, leucine, isoleucine, phenylalanine, and tyrosine and visceral obesity (25) . In our analyses, plasma AA alterations other than that of glutamate seemed to be related to overall adiposity rather than to specific visceral fat accumulation, and PCA confirmed this association pattern. Altered plasma AA, and AA-related catabolic products such as 2-aminoadipic acid (2-AAA), Kyn, and C5 acylcarnitine were also related to insulin resistance. This result is consistent with previous studies reporting impaired AA, and especially BCAA metabolism, in obese and insulinresistant subjects (4, 8, 33, 51) . Interestingly, our results suggest that the association between plasma BCAA and obesity is independent of insulin resistance level assessed by HOMA-IR. This finding may be reconciled with previous reports (8, 34) by considering potential sites for BCAA metabolism. In addition to impaired BCAA catabolism in adipose tissue, reduced protein synthesis by insulin-resistant muscles may also contribute to the plasma AA pool (41) . Liver was also shown to be an important site of BCAA catabolism. Liver steatosis has been associated with these mechanisms and could also possibly contribute, in part, to the elevation of plasma AA observed in diabetic patients. Our results underline the fact that, even in the absence of pronounced insulin resistance, adipose tissue dysfunction and obesity are sufficient to see increased AA levels in circulation. We propose that plasma AA level alterations are mostly associated with overall adiposity but may be worsened in the presence of insulin resistance, type 2 diabetes, or the metabolic syndrome.
Adipose tissue is thought to be an important regulator of whole body BCAA homeostasis (15, 19) . For example, Her- man et al. (15) demonstrated that BCAT2 knockout mice transplanted with perigonadal fat from wild-type mice had lower blood BCAA levels compared with nontransplanted knockout mice. Another report found that BCKDHA, BCK-DHB, and dihydrolipoamide dehydrogenase expression was reduced in subcutaneous adipocytes of obese individuals (19) . Considering that the first step of BCAA catabolism by BCATm produces glutamate, it could be possible that the accumulation of glutamate observed in visceral obese patients is due to altered BCKDC expression or activity. We observed that expression of genes from the BCKDH complex as well as BCAT2 were decreased in visceral fat of obese individuals. These results are consistent with those of Lackey et al. (19) , who showed lower expression of BCKDA and BCKDB spe- , total BCKDE1␣, BCKDE1␣ Ser 293 /BCKDE1␣, BCATm and BCKDK protein levels in subcutaneous adipose tissue among patients stratified for BMI. *P Ͻ 0.05. Protein levels were normalized to total actin levels. Lanes were run on the same gel but were noncontiguous; n ϭ 5-8.
cifically in visceral adipose tissue of obese individuals with or without metabolic syndrome. In addition, we also observed reduced expression of BCAT2 and the unaltered expression of BCKDK in the same depot. Only BCAT2 expression was reduced in the subcutaneous tissue of obese women. These results indirectly suggest that catabolism of BCAA is decreased in adipose tissue, particularly in the omental depot. Since catabolism of BCAA and ␤-oxidation of fatty acids occur in mitochondria, substrate abundance could overload this organelle and contribute to decrease BCAA catabolism in obese individuals. Yehuda-Shnaidam et al. (56) showed that adipocyte mitochondrial content was similar in obese and lean individuals. This observation supports the hypothesis that mitochondria of obese individuals could be less efficient. Accordingly, Yin et al. (57) demonstrated that mitochondrial function decreased independently of cell size and fat depot in obese individuals.
Despite growing evidence that obesity involves a defect in BCAA-catabolizing enzymes and/or gene expression (15, 19) , the impact of obesity on protein abundance and their activation status remains poorly investigated. She et al. (40) have shown that elevated BCAA levels are coincident with decreased BCKDE1␣ and BCATm protein levels in adipose tissue of two animal models of obesity in the fed state. The activation state of the enzyme, based on Ser 293 phosphorylation, was not affected. This group also performed Western blotting analysis on subcutaneous and visceral adipose tissue of morbidly obese individuals before and after bariatric surgery. They observed a significant increase in BCATm and BCKDE1␣ protein levels in both visceral and subcutaneous adipose samples obtained 17 months after the surgery on average. There was no difference in BCKDK protein level after the intervention (25) . These authors had not looked at the effect of obesity per se. Our data now provide clear evidence that obesity is associated with reduced BCKDE1␣ mass without any impact on Ser 293 phosphorylation. These effects are observed in visceral and not subcutaneous fat, which is in contrast to the fact that both fat depots responded similarly after gastric bypass-mediated weight loss in the She et al. study. Reduced visceral adipose tissue expression and protein levels of enzymes from the BCKD complex could contribute to the increase in circulating glutamate and BCAA levels of obese individuals. Further mechanisms include signaling through mTOR and eNOS induction (48) . Mechanisms of improved glycemia seem to include BCAA signaling or metabolism. However, improved insulin response might be due to distinct regulatory pathways in surgery-vs. diet-induced weight loss. BCAA levels are significantly lowered by gastric bypass but not by dietary treatment (20) .
We found strong positive associations between the Kyn/Trp ratio and adiposity indexes. Kynurenine is a metabolite of tryptophan degradation, and previous studies (23, 24) suggested that the Kyn/Trp ratio could be a potent indirect indicator of indoleamine 2,3-dioxygenase (IDO), a rate-limiting enzyme of tryptophan catabolism. This pathway is induced by proinflammatory cytokines, especially interleukin-2, TNF-␣, and interferon-␥ (24). We did not find associations between the Kyn/Trp ratio and TNF-␣ levels, possibly because inflammatory alterations in our sample were generally mild, the differences in TNF-␣ concentration among BMI groups being nonsignificant.
Since glycerophospholipids and sphingolipids are present in membranes and participate in lipoprotein transport and metabolism, associations between these metabolites and blood lipids were expected. We observed many significant associations between PC-and SM-related factors with variables of the blood lipid profile. Graessen et al. (12) showed a decrease in many PC species with improvement of the blood lipid profile in patients who had undergone Roux-en-Y gastric bypass surgery. In our study, we found that levels of PCaa, the most abundant phosphatidylcholine subtype, correlated with plasma cholesterol and triglyceride levels. Moreover the PCaa-related factor was a correlate of VLDL and HDL lipid content, consistent with the presence of these compounds at the surface of lipoproteins. Conversely, the PCae-and SM-related factors were related to higher levels of cholesterol-rich lipoproteins. Moreover, PCA analysis showed that the factor related to LysoPC was negatively associated with most adiposity markers but not with the blood lipid profile. These results on PC and LysoPC are consistent with those of Barber et al. (2) , who observed higher plasma PC species in mice fed a high-fat diet and lower levels of LysoPC in mice and obese diabetic or nondiabetic humans (2) . Moreover, 1-linoleoylglycerophosphocholine (L-GPC), or LysoPC C18:2, has been associated with peripheral insulin sensitivity and lower risk of developing impaired glucose tolerance in a large sample of subjects, even after adjustment for sex, age, BMI, and family history (6, 9) . In our sample of women, LysoPC C18:2 and other LysoPC species are included in PCA Factor 8, which was exclusively correlated with adiposity and BMI instead of insulin resistance measured with HOMA-IR. Miao et al. (30) reported that some LysoPC species were increased, while others were lowered, in hyperlipidemic rats fed a high-fat diet for 6 wk. Another study in mice fed a high-fat diet showed elevation in blood and liver of PC species that were associated with increased fat accumulation whereas most LysoPCs were decreased and some others were increased (17) . Similar results were observed in humans by Kim et al. (18) , where specific LysoPC species (14:0 and 16:0) were increased in overweight and obese men whereas LysoPC C18:1 was decreased. Other types (18:2 and 20:2) were not different among BMI categories. These results emphasize the need to consider specific LysoPC subspecies while correlations between PCs and parameters of the blood lipid profile or adiposity indexes appear to be more consistent from one study to another.
We assessed whether dietary AA intake was related to circulating AA levels, since Newgard and al. (33) had observed higher plasma BCAA concentrations in rats fed a BCAAenriched diet. In humans, a study by Tai et al. (45) showed that, among individuals stratified for their HOMA index and having normal BMI, insulin resistance was positively correlated with plasma BCAA levels independently of protein intake. We found no association between plasma AA levels and their respective dietary intake. Our results are consistent with a study from Piccolo and al. (34) , wherein obese women were enrolled in a weight loss trial and randomized in a 20 g/day whey supplementation vs. a gelatin control group. They did not observe a significant increase in BCAA plasma levels in the supplementation group compared with controls. We conclude that increases in plasma BCAA and other AAs observed in women with obesity are mostly independent of the diet. Possible bias associated with the use of dietary records, especially in obese individuals (10, 35) needs to be considered as a limitation of our analysis.
Additional limitations are also acknowledged. Our sample did not include men, which prevented us from assessing sex differences. In addition, our cross-sectional design prevented us from making inferences on potential cause and effect relationships. Finally, none of our participants were diagnosed with type 2 diabetes. In fact, most had fasting glycemia within the normal range; thus, potential associations between altered indexes of glucose homeostasis and the metabolome may have been underestimated in these subjects. The fact that association patterns were detectable in the absence of overt type 2 diabetes may point toward subclinical mechanisms effective even in obese individuals that are relatively healthy from the metabolic standpoint.
In conclusion, our analysis supports the documented elevation of plasma AA, particularly BCAA, and some of their metabolites in obesity. Alterations in BCAA-catabolizing enzyme expression and protein levels were mostly specific to visceral fat and may contribute to their increase in circulation.
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